Active Ingredient History
Lamotrigine (marketed as Lamictal) is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known. One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC50 for lamotrigine effects on NMDA-induced currents (in the presence of 3 uM of glycine) in cultured hippocampal neurons exceeded 100 uM. The mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established. The mechanisms that underpin the passage of lamotrigine at the blood-brain barrier to its site of action in the brain is poorly understood. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcoholism (Phase 4)
Allergy and Immunology (Phase 2)
Anxiety Disorders (Phase 3)
Asthma (Phase 4)
Bariatric Surgery (Phase 4)
Behavior, Addictive (Phase 2/Phase 3)
Binge-Eating Disorder (Phase 3)
Borderline Personality Disorder (Phase 4)
Brain Injuries (Phase 1/Phase 2)
Cerebral Palsy (Phase 4)
Cocaine-Related Disorders (Phase 4)
Cognition Disorders (Phase 2)
Crying (Phase 4)
Cyclosteroids (Phase 4)
Cystitis, Interstitial (Phase 2)
Dementia (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Dermatology (Phase 2)
Drug Resistant Epilepsy (Phase 4)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Epilepsy, Absence (Phase 3)
Epilepsy, Tonic-Clonic (Phase 4)
Esophagitis (Phase 1)
Fasting (Phase 1)
Glioma (Phase 4)
Healthy Volunteers (Phase 4)
HIV Infections (Phase 1)
Lamotrigine (Phase 4)
Mania (Phase 4)
Memory Disorders (Phase 4)
Meniere Disease (Phase 3)
Mental Disorders (Phase 1)
Mood Disorders (Phase 3)
Multiple Sclerosis, Chronic Progressive (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Myotonia (Phase 3)
Myotonia Congenita (Phase 3)
Myotonic Disorders (Phase 3)
Neoplasms (Phase 3)
Neuralgia, Postherpetic (Phase 2/Phase 3)
Neurofibromatosis 1 (Phase 2/Phase 3)
Neuronal Plasticity (Phase 2)
Neurotic Disorders (Phase 2)
Obesity (Phase 3)
Obsessive-Compulsive Disorder (Phase 2)
Opioid-Related Disorders (Phase 2)
Pain (Phase 4)
Paralysis, Hyperkalemic Periodic (Phase 3)
Psychiatry (Phase 2)
Psychomotor Performance (Phase 2)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Schizophrenia (Phase 4)
Seizures ()
Stress Disorders, Post-Traumatic (Phase 3)
Therapeutic Equivalency (Phase 1)
Trigeminal Neuralgia (Phase 2/Phase 3)
Vertigo (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
